Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Shockwave Medical (NASDAQ:SWAV) on Monday, setting a price target of $250, which is approximately 20.61% above the present share price of $207.28.
Antalffy expects Shockwave Medical to post earnings per share (EPS) of -$0.01 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Shockwave Medical, with an average price target of $218.75.
The analysts price targets range from a high of $250 to a low of $200.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $55.91 million and a net profit of -$180 thousand. The company's market cap is $7.29 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.1% and a 61.38% success rate.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins (NASDAQ:HWKN), John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.